Report Description Table of Contents How Are Oral Drug Delivery Innovations and Metabolic Therapies Transforming the Global Oral Proteins and Peptides Market? – (Updated On: 18th-Nov-2026) According to Strategic Market Research, the Global Oral Proteins and Peptides Market was valued at USD 6.50 billion in 2025 and is projected to reach USD 17.62 billion by 2032, growing at a CAGR of 15.3% during 2026–2032. Oral semaglutide remains the market's established revenue contributor, while new approvals for obesity, psoriasis, and cholesterol management are broadening the commercial applications of oral peptide medicines beyond traditional diabetes treatment. Oral proteins and peptides are therapeutic medicines containing amino-acid chains or protein-based molecules administered by mouth rather than injection. They are primarily developed as tablets and capsules, while certain oral films are designed for absorption through the mouth. Oral administration offers an alternative for patients requiring long-term treatment, particularly in diabetes, obesity, and other chronic conditions. However, developing effective oral formulations remains challenging because many therapeutic peptides and proteins are unstable during digestion and are poorly absorbed. Gastrointestinal degradation and limited absorption remain major barriers to oral peptide commercialization. Stomach acid and digestive enzymes can degrade these medicines before they reach the bloodstream, while the intestinal mucus layer and epithelial barrier restrict absorption. A 2025 review published in Pharmaceutics reported that oral bioavailability for many peptide and protein therapeutics is typically below 1%, with some candidates demonstrating even lower absorption. The limitation is particularly important for larger therapeutic proteins, which remain less commercially established in oral form than smaller peptide medicines. New formulation approaches are expanding the range of peptides being investigated for oral treatment. Pharmaceutical research includes structural modifications, protective tablet and capsule formulations, absorption enhancers, enzyme inhibitors, and specialized carriers intended to improve stability and absorption. Experimental approaches also include nanoparticle-based delivery, oral films, and gastrointestinal delivery devices. A 2026 scientific review identified these approaches as major areas of ongoing development, while noting that several remain at preclinical or investigational stages. The commercial feasibility of oral peptide delivery is already demonstrated by semaglutide. The FDA's 2026 prescribing information reports approximately 0.4%–1% absolute bioavailability for specified Rybelsus tablet doses. The formulation uses an absorption enhancer, allowing clinically effective oral treatment despite limited absorption. This distinguishes commercially established oral peptide products from investigational delivery approaches that have not yet generated comparable pharmaceutical revenue. Prescription growth provides direct evidence of increasing commercial adoption. According to Novo Nordisk's November 2026 financial report, Wegovy oral tablets recorded approximately 3.6 million prescriptions in the United States during Q3 2026, exceeding 8 million cumulative prescriptions since the January 2026 launch. The product's introduction established a new oral peptide treatment option in weight management, alongside existing oral semaglutide medicines for type 2 diabetes. Regulatory approvals are extending oral peptides beyond metabolic treatment. In March 2026, the U.S. FDA approved Johnson & Johnson's Icotyde (icotrokinra) for eligible patients with moderate-to-severe plaque psoriasis. The approval was supported by four clinical trials involving 2,500 participants across 17 countries. The product establishes an additional approved oral peptide application in dermatology, where treatment has traditionally included injectable biologics and conventional oral medicines. Cardiovascular drug development represents another potential commercial application. Merck's investigational oral PCSK9 inhibitor, enlicitide decanoate, is undergoing Phase III evaluation. Its CORALreef Outcomes study has a planned enrollment of approximately 14,550 participants and is evaluating cardiovascular outcomes. The program remains investigational, with no approved-product sales attributable to enlicitide at present. Osteoporosis is also attracting development of oral alternatives to injectable peptide medicines. In October 2026, Entera Bio presented the design of its planned Phase III EB613 study involving approximately 900 postmenopausal women with osteoporosis. Its November 2026 business update confirmed preparations for the first clinical site activation. EB613 remains a development-stage product, representing a potential future application rather than an established revenue contributor. International launches are extending the availability of approved oral peptide medicines. Novo Nordisk reported that Wegovy oral tablets had entered eight countries by early November 2026, including the United States, United Kingdom, Germany, and United Arab Emirates. These launches establish commercial activity across multiple regions, although product approvals and actual sales differ by country. Which FDA-Approved Oral Peptides, New GLP-1 Medicines, and Emerging Therapies Are Expanding the Market? FDA-Approved Oral Peptide Medicines Oral Semaglutide — Diabetes and Weight Management Novo Nordisk markets oral semaglutide through Rybelsus, Ozempic tablets, and Wegovy oral tablets. Rybelsus established oral GLP-1 treatment for type 2 diabetes, while the FDA approved the next-generation Ozempic tablet formulation in February 2026. The FDA's December 2025 approval of Wegovy oral semaglutide 25 mg expanded approved oral peptide treatment into chronic weight management and cardiovascular risk reduction among eligible adults. The OASIS 4 study reported approximately 16.6% mean weight loss among participants adhering to treatment. Oral semaglutide remains the clearest established commercial example of peptide absorption technology supporting large-scale pharmaceutical sales. MYCAPSSA — Oral Octreotide for Acromegaly MYCAPSSA (oral octreotide) received FDA approval in June 2020 for long-term maintenance treatment of acromegaly in patients who previously responded to and tolerated injectable octreotide or lanreotide. Its approved use establishes a specialized oral peptide market outside diabetes and obesity. The product demonstrates commercial participation in endocrine disorders, although its revenue opportunity is concentrated in a substantially smaller patient population than metabolic therapies. ICOTYDE — Oral Peptide Treatment for Psoriasis Johnson & Johnson's ICOTYDE (icotrokinra) received U.S. FDA approval in March 2026 for moderate-to-severe plaque psoriasis in eligible adults and adolescents aged 12 years and older. It is an oral peptide targeting the interleukin-23 receptor, representing a distinct treatment category beyond GLP-1 medicines. The European Medicines Agency granted marketing authorization in September 2026, extending its regulatory presence into Europe. Its commercial contribution will emerge through prescription sales following launch rather than through clinical-trial activity. LIPFENDRA — Approved Oral PCSK9 Peptide for Cholesterol Management On July 16, 2026, the U.S. FDA approved Merck's LIPFENDRA (enlicitide) for reducing LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. In Phase III trials, the product demonstrated approximately 56%–59% placebo-adjusted LDL-cholesterol reductions at 24 weeks in the reported study populations. Its approval adds a commercially relevant cardiovascular application for oral macrocyclic peptides. The larger CORALreef Outcomes study continues to evaluate cardiovascular events, while the approved cholesterol-lowering indication establishes a separate commercial opportunity. Non-Peptide Oral GLP-1 Medicines: An Emerging Competitive Category FOUNDAYO (Orforglipron) — Approved Oral Small-Molecule GLP-1 Treatment On April 1, 2026, the FDA approved Eli Lilly's FOUNDAYO (orforglipron) for chronic weight management in eligible adults. The once-daily medicine is a non-peptide small-molecule GLP-1 receptor agonist and can be taken without the food and water timing restrictions associated with oral semaglutide. The ATTAIN clinical development program established its efficacy in weight management, while the ACHIEVE program evaluates diabetes applications. Although FOUNDAYO competes directly with oral peptide GLP-1 medicines, its non-peptide chemical classification places it outside revenue attributed specifically to therapeutic peptides and proteins. Elecoglipron — Clinical-Stage Oral GLP-1 Competition AstraZeneca is developing elecoglipron (AZD5004), an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. The company's Phase III Eluminate-2 study is comparing elecoglipron with oral semaglutide in approximately 1,200 adults with type 2 diabetes. Additional pivotal trials are evaluating weight management among adults with obesity or overweight. These studies create potential future competition for established oral semaglutide products, but elecoglipron remains investigational and should not be included in approved oral peptide revenue. Source: Canadian Clinical Trial Registry, updated November 2026 Delivery Innovations and Clinical Pipeline Developments Absorption Enhancers and Protective Formulations Approved oral semaglutide demonstrates the commercial relevance of absorption enhancers such as SNAC. Pharmaceutical development is also examining enteric coatings, enzyme inhibitors, lipid-based carriers, and specialized capsule formulations to improve oral delivery of therapeutic proteins and peptides. These approaches address gastrointestinal degradation and limited absorption, although their commercial maturity differs substantially. Approved products provide direct pharmaceutical sales evidence, while most experimental delivery technologies remain associated with research and clinical development. Next-Generation Oral Peptide Candidates Beyond approved GLP-1 and PCSK9 medicines, research programs are evaluating oral insulin, oral amylin analogs, oral parathyroid hormone therapies, and oral GLP-2 candidates. Entera Bio's EB613 and EB612 programs represent endocrine applications, while oral amylin development introduces another potential treatment category within metabolic medicine. Novel peptide modifications and specialized delivery approaches are also being investigated for medicines traditionally administered by injection. Their future contribution depends on successful clinical trials and regulatory approval, rather than the number of compounds under investigation. Emerging Multi-Agonist and Small-Molecule Alternatives Pharmaceutical development also includes oral GLP-1 multi-agonists, longer-duration oral candidates, and experimental compounds such as IBI3042. These programs broaden competition in metabolic treatment, but their classification must be assessed individually because small-molecule receptor agonists are not necessarily therapeutic peptides. The distinction is important when evaluating the commercial potential of oral peptides separately from the wider market for oral metabolic medicines. Regulatory Developments and Compounded Peptide Products FDA oversight is distinguishing approved peptide medicines from unapproved wellness and compounded products. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed peptide substances including BPC-157, KPV, TB-500, and MOTS-C for possible inclusion on the federal compounding bulk-substances list. A separate October 2026 federal notice addressed conditional enforcement discretion for certain compounded peptide substances. These regulatory discussions do not constitute FDA drug approval. Similarly, collagen supplements and wellness peptides sold as dietary supplements are not FDA-approved treatments for medical conditions. Revenue from supplements, research-only peptides, and unapproved compounded preparations remains separate from the approved therapeutic Oral Proteins and Peptides Market. Which Product Types and Therapeutic Classes Account for Oral Proteins and Peptides Market Revenue? Product Type Segmentation Peptide Therapeutics — Largest Product Category Peptide therapeutics account for an estimated 82% of global market revenue, equivalent to USD 5.330 billion in 2025, and are projected to record the fastest product CAGR of 15.7% during 2026–2032. Their leading position is supported by commercially available oral semaglutide products, particularly Rybelsus, which established the oral GLP-1 treatment market before the introduction of newer obesity and diabetes formulations. The category also includes approved therapeutic peptides used outside metabolic disease. Its revenue contribution is more readily supported by identifiable commercial medicines than the protein and conjugate categories. Protein Therapeutics — Limited Established Oral Commercialization Protein therapeutics represent an estimated 13% share, equivalent to USD 845 million in 2025, and are projected to grow at a CAGR of 12.8%. Larger therapeutic proteins face more substantial gastrointestinal absorption limitations than many smaller peptides. Oral insulin is one of the principal areas of pharmaceutical research, but approved systemic oral protein medicines remain limited. The supplied revenue allocation therefore requires product-specific verification and should not be interpreted as independently confirmed sales from approved oral protein treatments. Peptide-Protein Conjugates — Emerging Therapeutic Category Peptide-protein conjugates account for an estimated 5% share, equivalent to USD 325 million in 2025, and are projected to grow at a CAGR of 14.9%. This category involves specialized therapeutic molecules intended to combine peptide-related activity with modified molecular properties. Although development activity continues, approved oral products with separately disclosed revenue remain limited. The estimated market contribution requires a clear list of qualifying commercial medicines before it can be validated independently. Therapeutic Class Segmentation GLP-1 Receptor Agonists — Dominant Therapeutic Class GLP-1 receptor agonists account for approximately 76% of market revenue, equivalent to USD 4.940 billion in 2025, and are projected to expand at a CAGR of 16.3% during 2026–2032. Oral semaglutide accounts for the clearest established commercial contribution within this category. Its approved applications in type 2 diabetes, followed by the introduction of oral semaglutide for obesity in 2026, distinguish the GLP-1 segment from other therapeutic classes where oral delivery remains investigational. The continuing development of additional oral peptide agonists could introduce competition beyond Novo Nordisk's established portfolio. Insulin and Insulin Analogs — Investigational Oral Therapy Market Insulin and insulin analogs represent an estimated 9% of market revenue, equivalent to USD 585 million in 2025, with a projected CAGR of 9.9%. Oral insulin remains an important development objective because insulin treatment continues to rely primarily on injectable formulations. However, gastrointestinal degradation and inconsistent systemic absorption have limited the commercialization of oral insulin products. The stated revenue allocation is provisional and cannot currently be supported by a comparable base of approved oral insulin sales. Other Therapeutic Peptides and Proteins — Applications Beyond GLP-1 Other therapeutic peptides and proteins account for approximately 15% of market revenue, equivalent to USD 975 million in 2025, and are projected to grow at a CAGR of 12.7%. This category covers established products outside GLP-1 treatment and the potential development of additional medicines for dermatological, cardiovascular, gastrointestinal, and endocrine conditions. Icotyde provides a new approved example from 2026, while other candidates remain in clinical development. The 2025 allocation must exclude revenue from products that had not yet been approved or launched. How Are Therapeutic Applications and Oral Delivery Formats Influencing Market Revenue? Application Segmentation Diabetes Management — Largest Application Diabetes management accounts for an estimated 65% of market revenue, equivalent to USD 4.225 billion in 2025, and is projected to grow at a CAGR of 12.9% during 2026–2032. Its leading position is associated with established oral semaglutide treatment for type 2 diabetes. Novo Nordisk reported DKK 4.938 billion in Q3 2026 sales for its combined Ozempic pill/Rybelsus category, confirming a substantial ongoing commercial business. The newer Ozempic tablet product entered the U.S. market in May 2026, while Rybelsus was already commercially established. Obesity Management — Fastest-Growing Application Obesity management represents an estimated 28% of market revenue, equivalent to USD 1.820 billion in 2025, and is projected to record the fastest application CAGR of 20.2% through 2032. The January 2026 launch of Wegovy oral tablets introduced a dedicated oral semaglutide treatment for weight management. The product achieved DKK 5.394 billion in global sales during Q3 2026, establishing significant commercial activity during its first year. However, these sales belong to 2026 and cannot substantiate the segment's estimated 2025 revenue. The base-year obesity allocation therefore requires reconciliation with the commercial oral peptide products available during 2025. Gastrointestinal and Endocrine Disorders — Specialized Treatment Applications Gastrointestinal and endocrine disorders account for an estimated 7% share, equivalent to USD 455 million in 2025, and are projected to grow at a CAGR of 13.7%. This category covers specialized peptide applications beyond diabetes and obesity. Entera Bio's EB613 osteoporosis program and EB612 hypoparathyroidism program are examples of endocrine-related oral peptide development. These products remain investigational and are not independently verified contributors to 2025 commercial sales. The grouping should distinguish approved gastrointestinal therapies from future endocrine applications. Formulation Type Segmentation Tablets — Largest and Fastest-Growing Formulation Category Tablets account for an estimated 77% of market revenue, equivalent to USD 5.005 billion in 2025, and are projected to grow at a CAGR of 15.6%. Their leading position is supported by oral semaglutide, which has an established commercial tablet format. Approved products introduced during 2026 have extended tablet-based peptide treatment into weight management and psoriasis. The category also benefits from ongoing development of specialized oral tablets for cardiovascular and endocrine conditions, although investigational products remain outside current commercial sales. Capsules — Specialized Oral Delivery Development Capsules represent an estimated 19% share, equivalent to USD 1.235 billion in 2025, and are projected to grow at a CAGR of 14.7%. Development activity includes protective capsule formulations intended to improve peptide stability during gastrointestinal transit. These approaches are relevant to therapeutic molecules that cannot achieve adequate absorption through existing tablet formulations. However, the available commercial evidence is less established than that for oral semaglutide tablets, and the segment's estimated revenue requires verification against approved capsule-based products. Other Oral Formulations — Emerging Administration Formats Other oral formulations contribute approximately 4% of market revenue, equivalent to USD 260 million in 2025, and are projected to expand at a CAGR of 13.1%. This category includes alternative oral delivery formats under pharmaceutical investigation. Oral films designed for absorption through the mouth represent a distinct approach from swallowed tablets and capsules. Their inclusion in market revenue should depend on whether the report covers all orally administered peptides or specifically products absorbed through the gastrointestinal tract. Delivery Technology Segmentation Permeation Enhancers — Leading Delivery Technology Permeation enhancers account for an estimated 72% of market revenue, equivalent to USD 4.680 billion in 2025, and are projected to record the fastest delivery-technology CAGR of 15.7%. Their leading position is supported by the commercial use of absorption-enhancing technology in approved oral semaglutide formulations. This is the clearest example of an established delivery approach associated with substantial oral peptide medicine sales. The attributed revenue represents sales of qualifying finished medicines, not sales of absorption enhancers as standalone products. Enzyme Inhibitors — Investigational Protection Strategies Enzyme inhibitors represent an estimated 18% share, equivalent to USD 1.170 billion in 2025, and are projected to grow at a CAGR of 13.3%. Development activity focuses on reducing peptide degradation during oral administration. Although enzyme protection is an established research approach, the revenue attributed specifically to approved oral peptide medicines relying on this technology has not been independently established. The allocation requires product-level evidence distinguishing these formulations from medicines using other absorption approaches. Nanoparticle-Based Delivery — Early-Stage Development Category Nanoparticle-based delivery accounts for an estimated 10% of market revenue, equivalent to USD 650 million in 2025, and is projected to expand at a CAGR of 15.6%. Research includes lipid- and polymer-based carriers intended to improve stability and absorption of therapeutic molecules. Much of this activity remains experimental or investigational. Consequently, the supplied 2025 revenue cannot be treated as verified sales of approved nanoparticle-based oral peptide medicines without identifying the commercial products included. Which Distribution Channels and Treatment Settings Account for Market Revenue? Distribution Channel Segmentation Retail Pharmacies — Largest Distribution Channel Retail pharmacies account for an estimated 67% of global market revenue, equivalent to USD 4.355 billion in 2025, and are projected to grow at a CAGR of 15.4% during 2026–2032. Established oral semaglutide prescriptions for type 2 diabetes provide a recurring retail-pharmacy revenue base. With the introduction of oral weight-management treatment, the channel also serves an additional prescription market beyond diabetes. Novo Nordisk's reported U.S. availability of Wegovy oral tablets through more than 70,000 pharmacies in 2026 provides direct evidence of the product's retail distribution footprint. Online Pharmacies — Fastest-Growing Distribution Channel Online pharmacies represent an estimated 15% share, equivalent to USD 975 million in 2025, and are projected to record the fastest distribution CAGR of 18.5%. Their commercial role is associated with prescription fulfillment and home delivery of established oral metabolic medicines. The channel must be distinguished from manufacturer-operated patient programs and telehealth services, since prescriptions fulfilled by a conventional pharmacy should not be counted again as online-pharmacy revenue. Hospital Pharmacies — Specialist Treatment Supply Hospital pharmacies account for approximately 18% of market revenue, equivalent to USD 1.170 billion in 2025, and are projected to grow at a CAGR of 12.0%. Their contribution is associated with specialist treatment initiation and medicine supply through hospital-linked diabetes and endocrine services. Because approved oral peptide medicines are frequently continued outside hospitals, hospital dispensing represents a smaller share than established retail channels in the supplied market allocation. End-User Segmentation Homecare Settings — Largest End-User Category Homecare settings account for an estimated 60% of market revenue, equivalent to USD 3.900 billion in 2025, and are projected to grow at a CAGR of 16.9%. Their position reflects patients taking prescribed oral medicines during long-term diabetes treatment and, from 2026, obesity management. Homecare represents the setting in which medicines are used rather than a separate pharmaceutical distribution channel. Revenue attributed to homecare should therefore not be added to retail or online pharmacy revenue. Specialty Clinics — Metabolic and Endocrine Treatment Specialty clinics represent approximately 23% of market revenue, equivalent to USD 1.495 billion in 2025, and are projected to grow at a CAGR of 13.6%. Diabetes, obesity, and endocrinology clinics contribute through prescribing and monitoring approved oral peptide medicines. Dermatology specialists represent another emerging clinical setting following the 2026 U.S. approval of an oral peptide for psoriasis. The contribution of newly approved applications belongs to the relevant forecast years rather than the 2025 base year. Hospitals — Smaller Share of Ongoing Oral Treatment Hospitals account for an estimated 17% of market revenue, equivalent to USD 1.105 billion in 2025, and are projected to grow at a CAGR of 11.3%. Their contribution is associated with hospital-based prescribing and specialist management of patients receiving oral peptide medicines. Routine long-term administration generally occurs outside inpatient settings, which explains why the supplied end-user model places a larger contribution in homecare. Which Countries Have the Clearest Commercial Opportunities in Oral Peptide Medicines? United States — Established Sales and New Approved Therapeutic Applications The United States accounts for an estimated 37% of the Global Oral Proteins and Peptides Market, equivalent to USD 2.405 billion in 2025, and is projected to grow at a CAGR of 15.8% during 2026–2032. The country has an established market for oral semaglutide in type 2 diabetes and became the first launch market for Wegovy oral tablets in January 2026. Novo Nordisk's expansion of oral obesity treatment across retail pharmacies and prescription services establishes a measurable commercial market for non-injectable peptide medicines. The FDA's approval of an oral peptide for plaque psoriasis during 2026 also broadens the U.S. market beyond metabolic disorders. These developments distinguish U.S. commercialization from countries where comparable therapeutic applications remain investigational. China — High Forecast Growth Requiring Product-Level Validation China represents an estimated 9% of global revenue, equivalent to USD 585 million in 2025, and is projected to record the fastest country-level CAGR of 18.5% through 2032. Its estimated market position includes potential demand for oral metabolic medicines and the development of additional peptide-based therapies. However, the available material does not provide verified 2025 Chinese sales for the specific oral peptide products included in this estimate. The projected growth should therefore be distinguished from the documented commercial revenue reported in the United States. Country-level market validation requires evidence of qualifying product approvals and actual sales. Denmark — Headquarters of a Leading Oral Peptide Manufacturer Denmark's position in the oral peptide industry is closely associated with Novo Nordisk, the developer and commercial supplier of oral semaglutide for diabetes and obesity. The company's international oral peptide portfolio represents an important source of Denmark-linked pharmaceutical business activity. However, global sales generated by Novo Nordisk should be allocated to the countries where medicines are sold, rather than counted as Danish domestic market revenue. Denmark's contribution as a manufacturer and innovation center is therefore distinct from its national patient-treatment market. Germany — Addition of Oral Weight-Management Treatment Germany entered the commercial launch markets for Wegovy oral tablets during 2026, adding an approved oral peptide option in weight management alongside established diabetes treatment. The launch creates a distinct product category within Germany's prescription metabolic therapy market. Its actual revenue contribution has not been separately disclosed in the supplied evidence, so the launch should not be used to infer a national market share or prescription volume. United Kingdom — New Oral Obesity Product Availability The United Kingdom also became a Wegovy oral tablet launch market during 2026. This provides an identifiable commercial development beyond existing oral diabetes medicines. The introduction adds another treatment format for eligible patients seeking prescription obesity care. However, country-specific prescribing volumes and revenue attributable to the oral product remain necessary to determine its actual contribution to the UK oral peptide market. India — Established Approval of Oral Semaglutide India has an established regulatory basis for oral semaglutide treatment in type 2 diabetes. The Central Drugs Standard Control Organization's January 2024 record confirms a revised indication for Rybelsus tablets following the product's initial July 2020 approval. This provides direct evidence of an approved oral peptide medicine in the Indian market. India should therefore be assessed through actual semaglutide tablet sales and prescribing, rather than relying solely on its broader pharmaceutical manufacturing capabilities or future oral peptide development. Japan — Established Oral GLP-1 Commercialization Japan approved Rybelsus for type 2 diabetes in June 2020, followed by its commercial launch in February 2021. The product entered Japan's national drug pricing system before launch, establishing a regulated oral GLP-1 treatment market. The Japanese regulatory and commercialization record provides stronger evidence of existing oral peptide activity than general expectations of future adoption. Japan's market is therefore linked to established diabetes prescriptions, while additional oral peptide indications require separate authorization and commercial evidence. Which Companies Are Competing in the Global Oral Proteins and Peptides Market? Novo Nordisk — Established Commercial Revenue From Oral Semaglutide Novo Nordisk holds the clearest documented commercial position in oral peptide medicines through Rybelsus, Ozempic tablets, and Wegovy oral tablets. The company's Q3 2026 financial results reported DKK 5.394 billion in Wegovy pill sales and DKK 4.938 billion in combined Ozempic pill/Rybelsus sales. These disclosures establish revenue attributable specifically to oral semaglutide medicines, rather than the company's broader injectable GLP-1 portfolio. The company also reported commercial availability of Wegovy oral tablets in eight countries by early November 2026. Its approved products provide a benchmark for evaluating other oral peptide developers whose treatments remain in clinical trials. Source: Novo Nordisk Q3 2026 Results Johnson & Johnson — Approved Oral Peptide Treatment for Psoriasis Johnson & Johnson participates through Janssen Biotech's Icotyde, an oral peptide approved in the United States for eligible patients with moderate-to-severe plaque psoriasis. The medicine represents a significant commercial distinction from oral metabolic therapies because it serves a separate therapeutic area with an established biologics treatment market. Although approval has been confirmed, meaningful product-specific commercial revenue will need to be assessed through subsequent sales disclosures. Source: FDA Icotyde Approval Merck & Co. — Clinical Development in Cardiovascular Treatment Merck is developing enlicitide decanoate, an investigational oral peptide inhibitor of PCSK9. A Phase III study published in The New England Journal of Medicine in February 2026 reported substantial LDL-cholesterol lowering with enlicitide compared with placebo. Its larger cardiovascular outcomes study is assessing whether treatment reduces major cardiovascular events. The product remains investigational and should be evaluated as a potential future market entrant rather than an existing source of approved oral peptide revenue. Entera Bio — Oral Peptide Development in Osteoporosis Entera Bio is developing EB613, an oral parathyroid hormone peptide for postmenopausal osteoporosis, alongside EB612 for hypoparathyroidism. In February 2026, Entera expanded its collaboration with OPKO Biologics on the EB612 program. Its November 2026 report also confirmed preparations for late-stage development of EB613, with results from the planned Phase III study expected in 2028. The company therefore represents clinical-stage participation in endocrine oral peptides rather than an established pharmaceutical sales competitor. Source: Entera Bio November 2026 Update Other Relevant Competitors and Their Market Positions Eli Lilly and Company: Competes in diabetes and obesity medicines, including the development of non-peptide oral GLP-1 products. These products represent competitive alternatives to oral peptide treatments but should not be included in revenue attributed specifically to therapeutic peptides. Pfizer: Has participated in oral metabolic drug research, but a comparable current approved oral peptide revenue contribution has not been established in the supplied evidence. Its historical development activity should not be represented as current commercial sales. What Will Determine Oral Proteins and Peptides Market Growth Through 2032? The most substantial established revenue opportunity remains oral GLP-1 therapy. Commercial sales of oral semaglutide demonstrate that peptide medicines can achieve meaningful pharmaceutical revenue despite low gastrointestinal absorption. The approval of Icotyde extends commercial oral peptide treatment into psoriasis, while enlicitide and EB613 represent possible future expansion into cardiovascular disease and osteoporosis. Their contribution will depend on successful development and regulatory authorization; the investigational products should not be included in existing approved-medicine sales. Oral therapeutic proteins, oral insulin, and several advanced delivery technologies remain less commercially established. Gastrointestinal degradation, limited absorption, and consistent treatment exposure are continuing constraints. Recent scientific progress has expanded the number of candidates entering development, but it has not established comparable commercial revenue across every technology category. The principal market-sizing consideration is therefore the difference between revenue from approved oral peptide medicines and the potential value of investigational products. The supplied global forecast should be assessed against identifiable product sales, while uncertain categories require further validation. How Was the Oral Proteins and Peptides Market Assessed? The assessment covers finished therapeutic medicines containing orally administered peptides, proteins, and qualifying conjugates. Products are classified according to their active therapeutic molecule, approved application, formulation, and principal delivery approach. Commercial revenue is assessed through product-specific pharmaceutical sales, regulatory approvals, and prescription activity. Novo Nordisk's oral semaglutide products provide the clearest established revenue reference. Investigational candidates, including oral insulin, enlicitide, and EB613, are assessed as future opportunities and excluded from approved-product sales until commercialization. Swallowed tablets and capsules are distinguished from oral-mucosal formulations where relevant. Products using more than one delivery approach are assigned to one primary technology category to prevent double-counting. Injectable peptides, non-peptide oral GLP-1 medicines, and standalone delivery-platform research revenue are excluded from the finished oral therapeutic products market. Oral Proteins and Peptides Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 6.50 Billion Revenue Forecast in 2032 USD 17.62 Billion Overall Growth Rate CAGR of 15.3% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Therapeutic Class, By Application, By Formulation Type, By Delivery Technology, By Distribution Channel, By End User, By Geography By Product Type Peptide Therapeutics, Protein Therapeutics, Peptide-Protein Conjugates By Therapeutic Class GLP-1 Receptor Agonists, Insulin and Insulin Analogs, Other Therapeutic Peptides and Proteins By Application Diabetes Management, Obesity Management, Gastrointestinal and Endocrine Disorders By Formulation Type Tablets, Capsules, Other Oral Formulations By Delivery Technology Permeation Enhancers, Enzyme Inhibitors, Nanoparticle-Based Delivery By Distribution Channel Retail Pharmacies, Online Pharmacies, Hospital Pharmacies By End User Homecare Settings, Specialty Clinics, Hospitals By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Established oral semaglutide demand, expanding oral peptide applications in chronic disease treatment, development of formulations improving stability and absorption, demand for oral alternatives to injectable therapies Customization Option Available upon request Frequently Asked Question About This Report Q1. What is driving commercial growth in the oral proteins and peptides market? A1. Growing use of oral semaglutide for diabetes and obesity is supporting commercial growth. Novo Nordisk reported approximately 3.6 million U.S. Wegovy oral tablet prescriptions during Q3 2026, with more than 8 million cumulative prescriptions since its January launch. This demonstrates increasing demand for oral peptide-based metabolic treatments. Q2. How are recent drug approvals expanding the industry's therapeutic applications? A2. Recent approvals are extending oral peptide treatments beyond diabetes and obesity. The FDA approved Icotyde for moderate-to-severe plaque psoriasis in March 2026 and Lipfendra for cholesterol management in July 2026. These approvals create additional pharmaceutical revenue opportunities in dermatology and cardiovascular care. Q3. Which therapeutic class accounts for the largest share of market revenue? A3. GLP-1 receptor agonists dominate with an estimated 76% revenue share, equivalent to USD 4.94 billion in 2025. Oral semaglutide is the principal commercial contributor through Rybelsus and other approved tablet formulations. Its established use in diabetes and expansion into obesity treatment support this leadership. Q4. How are absorption technologies influencing adoption in the industry? A4. Absorption enhancers and protective formulations are helping overcome gastrointestinal barriers associated with oral peptide medicines. The FDA reports approximately 0.4%–1% absolute bioavailability for specified Rybelsus doses. Its formulation uses SNAC to support absorption, demonstrating the commercial importance of delivery technologies. Q5. Which countries offer the strongest commercial opportunities in the oral peptide market? A5. The United States represents the largest country-level opportunity, accounting for an estimated 37% of global revenue in 2025. India and Japan also have established oral semaglutide markets through approved Rybelsus formulations. Germany and the United Kingdom gained additional opportunities through the 2026 launch of Wegovy oral tablets. Q6. How is competition evolving among companies in the industry? A6. Competition is expanding beyond established oral semaglutide products. Novo Nordisk leads through its oral GLP-1 portfolio, while Johnson & Johnson has entered oral peptide dermatology through Icotyde. Merck is developing oral peptide treatments for cholesterol management, while Entera Bio is advancing candidates for osteoporosis and endocrine disorders. Q7. What factors could restrict future expansion of the market? A7. Limited gastrointestinal absorption and peptide degradation remain major commercial challenges. Oral bioavailability for many peptide and protein medicines is typically below 1%. Several emerging delivery technologies and oral protein candidates also remain investigational, making successful clinical development and regulatory approval important to future market expansion. Sources: Novo Nordisk – Announced FDA Approval of Wegovy Oral Semaglutide 25 mg on December 22, 2025, for Weight Management and Cardiovascular Risk Reduction in Eligible Adults Novo Nordisk – Wegovy Pill Approved in the United States Novo Nordisk – Reported DKK 5.394 Billion in Wegovy Pill Sales During Q3 2026 and Commercial Launches in Eight Countries by Its November 4, 2026 Update Novo Nordisk – Third-Quarter 2026 Financial Results and Oral GLP-1 Commercialization U.S. FDA – Approved ICOTYDE (Icotrokinra) on March 17, 2026, for Eligible Adults and Adolescents With Moderate-to-Severe Plaque Psoriasis, Supported by Four Trials Involving 2,500 Participants FDA – ICOTYDE Approval and Pivotal Clinical Trial Evidence European Medicines Agency – Records EU-Wide Marketing Authorization for ICOTYDE on September 18, 2026, Extending Its Regulatory Availability Beyond the United States EMA – ICOTYDE: European Authorization and Approved Uses Merck – Announced FDA Approval of LIPFENDRA (Enlicitide) on July 16, 2026, as an Oral PCSK9 Inhibitor for Adults With Hypercholesterolemia, Including Heterozygous Familial Hypercholesterolemia Merck – LIPFENDRA Approval Expands Oral Macrocyclic Peptides Into Cholesterol Management U.S. FDA – Reported Placebo-Adjusted LDL-Cholesterol Reductions of 56% and 59% in the Two Trials Supporting LIPFENDRA Approval, Which Together Included 3,207 Adults FDA – First Oral PCSK9 Inhibitor: Approval and Clinical Results Entera Bio – Its November 6, 2026 Update Described Preparations for a Planned Phase III EB613 Osteoporosis Study Enrolling Approximately 900 Postmenopausal Women Entera Bio – Third-Quarter 2026 Results and Oral Peptide Development Update U.S. FDA – Its 2026 Label Reports Absolute Bioavailability of Approximately 0.4%–1% for Specified Rybelsus Doses and 1%–2% for Specified Ozempic Tablet Doses, With Both Formulated Using SNAC FDA – Rybelsus and Ozempic Tablets: Oral Absorption and Prescribing Information U.S. FDA – Records MYCAPSSA Oral Octreotide Approval on June 26, 2020, for Long-Term Maintenance Treatment of Acromegaly in Patients Previously Responding to and Tolerating Octreotide or Lanreotide FDA – MYCAPSSA: Approved Oral Octreotide Indication U.S. FDA – Approved Eli Lilly’s FOUNDAYO (Orforglipron) on April 1, 2026, Adding a Once-Daily Oral GLP-1 Treatment Option for Eligible Adults With Obesity or Overweight FDA – FOUNDAYO Approval for Chronic Weight Management Table of Contents – Global Oral Proteins and Peptides Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, and End User Investment Opportunities in the Oral Proteins and Peptides Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Oral Semaglutide, GLP-1 Receptor Agonists, Oral Peptide Medicines, Protein Therapeutics, and Peptide-Protein Conjugates Investment Potential in Absorption Enhancers, Enzyme Inhibitors, Nanoparticle-Based Delivery, and Advanced Oral Formulations Emerging Opportunities in Diabetes Management, Obesity Management, Cardiovascular Treatment, Psoriasis, and Endocrine Disorders Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Oral Protein and Peptide Medicines in Chronic Disease Management Role of Oral Drug Delivery in Reducing Dependence on Injectable Therapies Commercial Importance of Oral Semaglutide and Emerging Therapeutic Applications Market Evolution from Established Oral Peptides to Emerging Protein-Based Medicines Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Assessment of Approved Oral Peptide and Protein Medicines Evaluation of Commercial Product Revenue and Prescription Activity Classification of Approved Products, Investigational Candidates, and Non-Peptide Alternatives Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals and Pharmaceutical Development Role of Oral Semaglutide in Expanding Commercial Adoption Impact of Gastrointestinal Degradation and Limited Oral Bioavailability Influence of Absorption Enhancers, Enzyme Inhibitors, and Protective Formulations Development of Oral Alternatives to Injectable Peptide Medicines Impact of Prescription Growth and International Product Launches Regulatory Distinction Between Approved Therapeutic Peptides, Compounded Products, and Dietary Supplements Global Oral Proteins and Peptides Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Peptide Therapeutics Protein Therapeutics Peptide-Protein Conjugates Market Analysis by Therapeutic Class: GLP-1 Receptor Agonists Insulin and Insulin Analogs Other Therapeutic Peptides and Proteins Market Analysis by Application: Diabetes Management Obesity Management Gastrointestinal and Endocrine Disorders Market Analysis by Formulation Type: Tablets Capsules Other Oral Formulations Market Analysis by Delivery Technology: Permeation Enhancers Enzyme Inhibitors Nanoparticle-Based Delivery Market Analysis by Distribution Channel: Retail Pharmacies Online Pharmacies Hospital Pharmacies Market Analysis by End User: Homecare Settings Specialty Clinics Hospitals Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Oral Proteins and Peptides Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, and End User Country-Level Breakdown: United States Canada Mexico Europe Oral Proteins and Peptides Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, and End User Country-Level Breakdown: Germany United Kingdom Denmark France Italy Rest of Europe Asia Pacific Oral Proteins and Peptides Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, and End User Country-Level Breakdown: China India Japan South Korea Rest of Asia-Pacific Latin America Oral Proteins and Peptides Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Oral Proteins and Peptides Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Novo Nordisk A/S Johnson & Johnson Merck & Co., Inc. Entera Bio Ltd. Eli Lilly and Company Pfizer Inc. AstraZeneca plc Sanofi S.A. Takeda Pharmaceutical Company Limited Amgen Inc. Chiesi Farmaceutici S.p.A. Hanmi Pharmaceutical Co., Ltd. Biocon Limited Zealand Pharma A/S Competitive Landscape and Strategic Insights Benchmarking Based on Approved Oral Peptide Portfolios, Therapeutic Applications, Formulation Technologies, and Commercial Presence Oral Semaglutide Portfolio Positioning Oral Peptide Development for Diabetes and Obesity Management Competitive Positioning in Dermatological and Cardiovascular Applications Clinical Pipeline Benchmarking for Oral Insulin and Endocrine Peptide Candidates Absorption Enhancement and Oral Delivery Technology Benchmarking Regulatory Approval, Product Launch, and Commercialization Capability Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources Regulatory Approval and Product Development References Scope and Classification of Approved and Investigational Oral Therapeutics List of Tables Market Size by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, End User, and Region (2026–2032) Historical Market Size and Volume Analysis (2019–2024) Base Year Market Size Analysis (2025) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Assessment for the United States, Canada, Mexico, Germany, United Kingdom, Denmark, France, Italy, China, India, Japan, South Korea, Brazil, Saudi Arabia, United Arab Emirates, and South Africa Competitive Benchmarking of Leading Oral Protein and Peptide Companies Approved Oral Peptide Medicines and Their Therapeutic Applications Investigational Oral Peptide and Protein Candidates Formulation and Delivery Technology Assessment Regulatory Approvals and International Product Launches During 2026 List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Therapeutic Class, Application, Formulation Type, Delivery Technology, Distribution Channel, and End User (2025 vs. 2032) Global Oral Proteins and Peptides Market Ecosystem and Value Chain Analysis Oral Semaglutide Commercialization and Product Expansion Oral Peptide Delivery Technologies and Absorption Enhancement Approaches Approved Medicines and Emerging Clinical Pipeline Across Therapeutic Applications